Member Info for Heimdal

Bignose, I currently have a Defender 110 Td5 model, my 3rd Land Rover and 2nd Defender. Lots of mechanical problems over the years lol, but still in love with Defenders. If ERP goes to +$1 I will certainly consider upgrading to the new Defender model for more comfort. The standard model is not that flash but add a few extras and they look great. The INEOS Grenadier is also worth considering. Sounds good with the Defender in Norway. Bring on 2022!

Merry Christmas Bignose and all. Congratulations on the new Qashqai. Still happy with my Defender but it
would probably not qualify for the Singapore roads lol

JP Morgan predict a sharp c. 40% rebound in the HK market in 2022 and I am confident we will benefit from the positive sentiment. 2022 should be a rip roarer with steady positive news flow in a rising market.

Onwards and upwards!

Good post Bignose. First time I have invested in pharma, it is a risky sector but with potential massive rewards. Certainly a waiting game. Not always things pan out well just look at Oncopeptides and Mountain Valley MD (which was promoted again and again on this bb by Charlie). MV is currently trading at 11c after a high of $2.29 back in February. ONCO was trading at 215 kr in February and is now at 8.8 kr. I am sure Endurance will deliver in due course. When Fortacin is finally on the shelves around the world the MCap will be multiples of 33m squid.

It sounds like the board is simply investigating the potential of a shift in regulatory strategy in order to speed things up.
"The Company’s CRO has requested a RLD Type C meeting with the FDA for the purposes of obtaining feedback from the division on the RLD protocol before the EOP2 meeting." As such the FDA feedback will be critical wrt a potential new strategy.

I agree with The.Italian that we are inching slowly forward. Not as fast as we wish but still progress on all fronts. I am very pleased that we are joining forces with Tel Aviv based SK Pharma Group. I notice they have world wide offices including Russia and Belarus so maybe they can assist us in expanding into these countries in due course. We might get a separate update on DLI developments when there is some tangible progress to report. Funding for 2022 is not an issue as we can very easy offload our DVP holding (which is still undervalued).

November 29, 2013, Chalgrove, United Kingdom - Plethora Solutions Holdings, a speciality pharmaceutical company, announces that Ronald Openshaw will step down from the board and resign as chief executive officer, effective November 30, 2013.

Mr. Openshaw has a significant track record in life sciences and healthcare sectors both in executive management and in an advisory role. He is the founder of the M&A and strategic consulting firm Lucia Capital LLP and previously he spent many years as an investment banker at Panmure Gordon & Co. Limited (latterly WestLB Panmure Limited) and then most recently Jefferies International Limited.

Mr. Openshaw also served as CFO and acting CEO at Pharmagene plc until its merger with Asterand plc in 2006, where he remained as CFO to complete the integration in early 2007. He qualified as a Chartered Accountant with KPMG.

RO on LinkedIn with an outdated headline stating: 2020 a year for Vision - Strategy - Action...

Lucia Capital Consulting has been my consultancy vehicle since 2008. Over that period I have helped many companies achieve a number of goals in corporate strategy, mergers, acquisitions, and disposals. In 2013/14 I helped Simbec Research - recently acquired by the Wales Life Sciences Fund - to acquire Orion Clinical. This led to my appointments as CEO of Simbec-Orion. Following my departure from this role I am now taking on a number of interesting projects, until a new C-suite role takes up my working day. ... Not a word about Plethora Solutions, I wonder why? The departure as CEO for PS was very abrupt, announced one day and gone the next with no acknowledgement wrt his contribution in moving the coy forward...

Thanks Bignose. Let's see how it all pans out. I am hopeful our patience will be well rewarded $$$$$$$$$.

Bothwell, on AUG 28 you noted: "His (ie. Alquemie) comments seem like someone who knows the facts, from a good basic training but decides to twist them…….hallmarks of an employee “who has been let go” ? Could be licensor trying to knock the price down (joke)."

"Who is right or wrong will play out over the next 12-18 months. As I’m sure you appreciate as the information could be price sensitive I can only expand slightly beyond what is on the website. On that basis, until we are over the goal line I can’t answer and more bb questions……apologise to the guys please but at this stage lots of interested parties are trying to get information."

I guess these are e.mail extracts from Dr Mike Wyllie and I find solace from the last bit part about lots of interested parties in the USA are trying to get information.

It is also important to remember that Bignose is a major holder in direct contact with Dr Mike Wyllie and he did not run for the hills unlike Charlie. I hope Charlie is OK after investing in AMC and Mountain Valley MD.

Strong finish from DVP yesterday @ 84c (on the old scale) with our holding now valued at $HK$101,354,352 or 30.6% of the MCap. If DVP is awarded the Bellevue Gold mining contract this month we should see a major leg up as the market will most likely assume other contracts will follow. Next months we will get 75% of the results from the recently completed $10m drilling program with resource upgrade to follow etc which should maintain upward sp momentum.

https://www.euroinvestor.dk/nyheder/podcast

Thanks Italian. DLI are pioneers in this area and it will interesting to see where they are in say in 2-3 years.
Young.AI is probably just the beginning. Dr Alex Zhavoronko is a prime mover in the longevity sector and
a major 575 shareholder and I am hopeful he will deliver in due course. Rome was not built in a day.
The name change on June 28 signals change and new developments but since then we have had prolonged radio silence
as such I guess something is going on behind the scene.

DVP currently trading at 82c on the old scale with our holding now equaling 29.8% of the MCap - basically shell value
so we could potentially see a major move north if the BoD get it together. As Bignose said it is probably very unrealistic to even dream of the $1b for Fortacin. However, as Dougie pointed out Jones long lasalle determined fair value of PSD502 to be around £167M so that might be the figure the BoD will go after, which should propel us back up to 70c.
Certainly strong headwinds in HK market this year as the Hang Seng index is down 21.2% since the Feb high and 575 tracking the index down. Since Jan Hang Seng is down 7.8%. However, 2022 could well be a rip roarer for emerging markets with 575 benefiting from decent tail winds and progress on all fronts (developing Cu story, DLI and FDA / North America, China and EU progress). I hope Jim and Jamie will hang on to our DVP holding for a while longer, after all they identified this solid high grade Cu play and were both on the board of VXR back in 2013 when Regent held 33.47% of the shares, so they are extremely familiar with the project.

Positive to see DVP powering ahead with our reduced holding now valued @ $17,257,268 (after paying the outstanding ATO bill in full). If we are awarded the Bellevue Gold Ltd (ASX:BGL) u/g mining contract this month we could see a major move north (in the DVP sp). Interesting to see how long ERP's BoD will maintain this key position. Significant upside here with the development of the SS Cu mine, resource upgrade, Cu prices poised to hit $15k/t and the new u/g mining division.

I heard a Swedish pharma Director a few days ago mentioning that many minor pharma companies simply offload their product / company after successfully completing FDA phase 2 to one of the major players. I wonder if this could happen here and possibly explain the prolonged radio silence?

I agree that our DVP holding is not significant in the overall scheme of things,however while we await the long overdue FDA/ /China/EU/operations update it is positive that the value of our holding is growing, and should grow further over the next few weeks and thus significantly underpin our sp.

Upcoming catalysts:

Major SS project status update due on DEC 14 with the assay results from ~25% of the resource and exploration holes drilled during the now completed $10m campaign .

News on the tender for the mining contract at Bellevue Gold’s (ASX: BGL) Bellevue project in Western Australia.

The latest preso from DEC 1 shows Sandvik u/g mining equipment with a DVP sticker so I guess Bill Beament must be fairly confident the first contract will be soon be awarded: https://wcsecure.weblink.com.au/pdf/DVP/02460537.pdf

On the longer track Bill Beament might well be successful in transforming DVP into a multi-billion $ coy, as previously stated, with the new u/g mining division and further progress at SS and beyond.

DVP is heading north again post 5:1 consolidation, now trading at A$3.76 which is 75.2c on the old scale:

https://www2.asx.com.au/markets/company/dvpdb

Our reduced holding is now valued at A$16,221,811 or HK$89.2m which is 25.8% of our current MCap of 33.4m squid.

It seems like DLI is expanding with a few new staff appointments:

Mariya Pankova, iOS Developer - start Sept 2021
?????? ????????, iOS Team Lead - May 2021
Ken Kam, Head of Business Development - Sept 2021
Michelle Keller Senior Manager of Scientific Business Development replaced PM during July 2021

LinkedIn now list 10 current DLI employees incl Alex

Polina Mamoshina is no longer on the list, she left DLI back in June. She mention on LinkedIn that she re-launched
Young.AI app with a 30,000 user base. Not sure if that is a full paying customer base?

I see DLI updated Young.ai 3 times during Sept-Oct (mainly fixing bugs), current version 1.1.6

Hopefully we will see some cash flow from DLI in the short term.

I don't recall Michelle Keller mentioning young-ai during her recent preso, maybe they are taking
a different direction now?

Dr Mike Wyllie is a seasoned pharma professional and he is still about. I believe Mike is doing his utmost to get Fortacin to the market.

Jim, Jamie and Alex have significant skin in the game with +33% of the issued shares and as such they have a major incentive to move the company forward in a big way.

bignose68, you should have moved on many many (as in many) years ago as you obviously don't have any faith in management.

Technology transforming medicine - New Deep Longevity video presentation by DLI senior manager of scientific Business Development Michelle Keller @ STEMulate 2021, an event organized by weareiWiS and STFC UK to amplify female scientific voices. Watch VOD here https://www.youtube.com/watch?v=xli_HpR1mVk

I notice Kenneth Kam was appointed Head of DLI Buisness Development in SEPT.

SP sold down on very low vol.

Wealthy funds are using algorithmic bots to manipulate small cap stocks like 575
to the detriment of mum and dad investors. HKSE market manipulation should be
investigated and prosecuted.

Hang Seng Index down 7% this year mainly generated by the constant interventions from Beijing,
unsettling the HK punters. Not an easy market for ERPG to operate in. The company have clearly
changed strategy from frequent operation updates late last year-early this year to nada, not sure why but hopefully some
news soooooooon.

VXR/DVP holding up fairly well with our reduced holding valued at around AU$13m.

Still hope as Dougie said.

Thanks for sharing Bothwell. Sounds like an e,mail directly from Dr Mike Wyllie. Happy to hold for another 12-18 months to see how this plays out. Heimdal

Not all doom and gloom:

- Return to profit
- Company remains exited about future prospects
- FDA Phase II milestone submission imminent
- Very positive results from marketing study in USA
- Ongoing licensing discussions with potential US partners
- Company pursuing further investments in health and life sciences sectors
- ATO tax bill paid in full
- Manufacturing issues resolved in Europe + significant scale up to 50,000 batch size
- Taiwan launch next month
- China clinical trials start in Oct
- DLI working with several leading insurance companies
- VXR significant increase in value of our holding
- Very low MCap of just GBP 39.8m - significant upside on good news

Heimdal

https://www.scmp.com/week-asia/opinion/article/3143981/hong-kong-equity-investors-may-well-give-and-kiss-hsi-goodbye

Not sure what Jim's game plan is Bignose, interesting times..